Expression of aminopeptidase N/CD13 in human ovarian cancers

International Journal of Gynecological Cancer

Volumn 16, Issue 5, 2006, Pages 1783-1788

  Surowiak, P ^a,b,c   Drag M ^d   Materna, V ^a   Suchocki, S ^e   Grzywa, R ^d   Spaczynski M ^f   Dietel, M ^a   Oleksyszyn, J ^d   Zabel, M ^b,f   Lage, H ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Wroclaw   (Poland)

^d WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^e Voivodship Hospital   (Poland)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CD13; Chemotherapy; Immunohistochemistry; Ovarian cancer

Indexed keywords

MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; PARAFFIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; OVARY CANCER; PRIORITY JOURNAL; SAMPLING; STATISTICAL SIGNIFICANCE;

AGED; ANTIGENS, CD13; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 33749154707     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00657.x     Document Type: Article

References (18)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
2. Steward BW, Kleihues P. World cancer report. Lyon, France: IARC Press, 2003.
3. Averette HE, Hoskins W, Nguyen HN et al. National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer 1993;71:1629-38.
4. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003;22:188-99.
5. Surowiak P, Materna V, Denkert C et al. Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett 2006;235:272-80.
6. Surowiak P, Materna V, Kaplenko I et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005;447:626-33.
7. Zasławski R, Surowiak P, Zabel M. Classical and novel molecular prognostic factors in ovarian cancers. Pol Merkuriusz Lek 2005;19:105-11.
8. Grujic M, Renko M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 2002;182:113-9.
9. Riemann D, Kehlen A, Langer J. CD13-not just a marker in leukemia typing. Immunol Today 1999;20:83-8.
10. Hashida H, Takabayashi A, Kanai M et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002;122:376-86.
11. Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 2003;63:8500-6.
12. Ikeda N, Nakajima Y, Tokuhara T et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 2003;9:1503-8.
13. Van Hensbergen Y, Broxterman HJ, Rana S et al. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res 2004;10:1180-91.
14. Sobin LH, Wittekind C, eds. TNM Classification of malignant tumors. New York, NY: UICC Wiley-Liss, 1997:152-7.
15. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
16. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
17. Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 1999;13:729-34.
18. Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Curr Drug Metab 2001;2:67-85.